Show simple item record

dc.contributor.authorLee, Stacey
dc.date.accessioned2010-03-15T19:37:18Z
dc.date.available2010-03-15T19:37:18Z
dc.date.issued2010-03
dc.identifier.urihttp://jhir.library.jhu.edu/handle/1774.2/34009
dc.description.abstractOver the next five years, approximately 110 drugs, including blockbuster products such as Sanofi-Aventis’ allergy medicine Flomax, GlaxoSmithKline’s herpes medication Valtrex, and Pfizer’s cholesterol medication Lipitor will lose their patent protection. In 2009 alone, brand-name drugs coming off patent were valued at more than 10.8 billion dollars. As market exclusivity for these drugs ends, the doors for generic production will open. Generic drugs generally enter the market priced 20 to 80 percent lower than their branded counterparts, and generics can capture 44 to 80 percent of brand-name drug sales within a year after release. This price competition from generic drugs threatens the profits of brand-name manufacturers and reduces their returns on innovative activity. As a result, some brand-name drug manufacturers have resorted to aggressive tactics to blunt the impact of competition.en
dc.language.isoen_USen
dc.relation.ispartofseriesThe Johns Hopkins Carey Business School Working Paper Series;2010-03-001
dc.subjectK2en
dc.subjectCitizen Petitionsen
dc.subjectShamen
dc.subjectNoerr-Penningtonen
dc.subjectGenericsen
dc.titleIs A CURE ON the WAY? – THE BAD MEDICINE OF GENERICS, CITIZEN PETITIONS, AND NOERR-PENNINGTON IMMUNITYen
dc.typeWorking Paperen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record